Novartis Investigative Site

Novara 28100

1 studies enrolling now · 15 studies all time

What they study most

ALK Positive Malignancies, Acute Heart Failure, Advanced Malignancies, Age-related Macular Degeneration, Atherosclerosis, Breast Cancer, Cardiovascular Disease and Lipoprotein(a), Chronic Kidney Disease (CKD), Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia, Coronary Artery Disease (CAD), Coronary Atherosclerosis

Studies at this site

• An Extension Study for Patients Previously Enrolled in Studies With Pelabresib — Recruiting now
• A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia — Running, not enrolling
• Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study — Running, not enrolling
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients — Completed
• Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) — Completed
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis — Completed
• Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) — Completed
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients — Completed
• Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia — NO_LONGER_AVAILABLE